Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
about
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnologyCancer stem cells and drug resistance: the potential of nanomedicineLipid-Based Nanocarriers for RNA DeliveryGalectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinomaCo-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapyCodelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumorLipid-based vectors for siRNA deliveryTargeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Recent advances in nonviral vectors for gene delivery.Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.Combination drug delivery approaches in metastatic breast cancerTargeted silencing of the oncogenic transcription factor SOX2 in breast cancerUtilisation of nanoparticle technology in cancer chemoresistance.Delivery of intracellular-acting biologics in pro-apoptotic therapies.Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots.Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery.Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.Multifunctional Nanographene Oxide for Targeted Gene-Mediated Thermochemotherapy of Drug-resistant Tumour.Strategies for tumor-directed delivery of siRNA.Antibody-targeted nanoparticles for cancer therapy.Recent advances of siRNA delivery by nanoparticles.Nanocarriers: a tool to overcome biological barriers in siRNA delivery.Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.A daunting task: manipulating leukocyte function with RNAi.Recent advances in delivery of drug-nucleic acid combinations for cancer treatmentMerging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Nanomaterials for targeted drug delivery to cancer stem cells.Nanodrug delivery in reversing multidrug resistance in cancer cells.A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination Therapy.
P2860
Q26849264-C5B1D1EA-9FA5-4EAA-8CC7-B60A9C24CF3DQ26998993-587C219F-4A64-420C-BB68-096F9A913751Q28080706-19C10478-D19D-4BE8-A902-022B46893FEAQ28535429-CC253B95-F2A9-491E-B56B-3814D5AEAC8DQ28541628-0BCF25C1-4808-41A1-AED7-5A5979AAFF9EQ28543911-7699A51F-93DA-41A1-83CF-BA7FFBDD5326Q28828356-EF76B3FE-717D-425F-B7FC-FCBB50CBF69BQ33735020-928247D0-AD94-428D-908C-27867FA22147Q33935474-E4DD3F25-695A-4663-93B6-1C9DE072FBC9Q33935498-585A8E58-D07C-4103-8E7B-D8AC2CDE54A0Q34361211-6248B88B-9E81-4C9C-8F08-B7ABAF56B82AQ34622662-C4B176B6-39C2-458A-91E8-F34D533C9C58Q35618915-E28862D7-172E-4FF9-8B07-2A0F1791E899Q35751958-8508F038-A63D-45D2-90D2-53A7162B8644Q35903717-84F15A2B-EB6B-4758-9018-B328ACD85E6CQ35924301-C5B380D3-F596-4626-A539-87C923E831BDQ35955198-4FD93ACF-D280-40C9-B1BD-6D1074E143F0Q36144913-A10728AF-EA23-4E0D-9993-6E6DAA5AA6E4Q36421258-9B0F9E05-3FC6-4B86-A379-A3B6691D1318Q36588920-BDA0E7DC-4FD9-40AB-811B-AC71C08ADBFBQ36749553-3D4E6814-613E-4518-9473-CE43C87BA2DAQ37031597-8A186733-8C98-4DB2-9F66-3FBC13CC5E0BQ37214403-FE938581-3758-444C-B75F-C8723F9D1316Q37251480-2E20F921-9FF9-4D7C-BC97-1870B0EB8B35Q37254863-09F51CFB-0770-479C-8B37-ABFB197FD31CQ37495209-E8676693-94AC-4EDB-8423-0B0B57697BD9Q37685914-9038C5B7-8ACE-4FC3-B0B1-F5FB81F19875Q37840092-AF9952D3-6910-4882-ACC4-19EF0E36B8BAQ37851969-BA4AD9BA-78E6-4A4A-9813-97601DF7FDAFQ37854061-A51BCAF8-FD68-40A3-B406-948DB8A26E99Q37891091-ACF0D032-EEE1-46E9-8D8C-34CBFEFE3827Q37938830-99E3D8C4-103F-43D9-96D4-7A04246BBA9AQ38074442-27C93521-FB90-46FC-94FF-F8E68A7135EAQ38095502-8DE39EEE-3972-46AC-8085-6BAD5D6A1990Q38102522-99A39E5D-9BE7-4B6B-AB9D-A01E3F7554C4Q38150118-9885A1BF-E74E-4D7C-8B45-25FE18C64CEDQ38183852-DF79D9C2-7313-472C-99F4-A7BF88732878Q38201740-5F3205FA-2706-4386-AF12-9B6D4E81FB88Q38234908-7DA63212-415E-43CD-95C3-CBBFB97735E0Q38647298-579230E8-CD31-4922-9BEC-FDF1C3766C98
P2860
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Multifunctional nanoparticles ...... ome drug resistance in cancer.
@ast
Multifunctional nanoparticles ...... ome drug resistance in cancer.
@en
type
label
Multifunctional nanoparticles ...... ome drug resistance in cancer.
@ast
Multifunctional nanoparticles ...... ome drug resistance in cancer.
@en
prefLabel
Multifunctional nanoparticles ...... ome drug resistance in cancer.
@ast
Multifunctional nanoparticles ...... ome drug resistance in cancer.
@en
P2093
P2860
P356
P1476
Multifunctional nanoparticles ...... come drug resistance in cancer
@en
P2093
Leaf Huang
Surendar Reddy Bathula
P2860
P304
22639-22650
P356
10.1074/JBC.M110.125906
P407
P577
2010-05-11T00:00:00Z